机译：A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson's disease: translational gaps or a failing industry innovation model?
Alcyoneus Sci LLC, Sparta, NJ 07871 USA;
Partnership Assessment & Accreditat Sci Practice, Heidelberg, Germany;
Ventral Stream Consulting LLC, Lake Bluff, IL USAAddex Therapeut, Geneva, Switzerland;
Allosteric drugs; drug discovery and development; foliglurax; mGluR4 PAM; nondopaminergic mechanisms; off periods; parkinson; 8217; s disease; pharmaceutical business models; preclinical efficacy models; translational PET imaging;
